Navigation Links
Novel MR-guided radiation therapy platform highlighted at ASTRO meeting
Date:9/26/2013

ATLANTA, Sept. 26, 2013 /PRNewswire/ -- IMRIS Inc. (NASDAQ: IMRS; TSX: IM) and Varian Medical Systems (NYSE: VAR) today announced that data presented here earlier this week at the American Society for Radiation Oncology (ASTRO) Annual Meeting demonstrates the potential to direct state-of-the-art radiation treatments using diagnostic-quality MR images at each treatment session.

In a presentation to radiation oncology clinicians from around the globe, David Jaffray, PhD, a world-renowned radiation physicist at the Princess Margaret Cancer Centre and Director of the Techna Institute at the University Health Network (UHN) in Toronto, described a dedicated MR-guided radiation therapy suite that will allow a magnetic resonance (MR) scanner mounted on ceiling rails to perform MR-guided brachytherapy and external beam radiation delivery. Currently being installed at his institution, this unprecedented combination is a joint development combining IMRIS' MR imaging with Varian's TrueBeam® system for image-guided radiotherapy and radiosurgery.

"Tightly integrating MR imaging with treatment is expected to allow us to increase the accuracy of radiation delivery and pursue research in the emerging field of adaptive radiation therapy – the next level of image-guided radiotherapy that seeks to modify the treatment in response to changes in patient anatomy," said Jaffray. The team at the Princess Margaret has been performing research on the use of MR in radiation therapy as well as studying how the MR and radiation treatment technologies can be made compatible.

"While it is premature to speak to the clinical benefits of the development," he added, "the technical advantage of enhanced visualization of the tumor and normal tissues at the time of treatment opens many possibilities." The Princess Margaret team is planning to explore the system's use in the treatment of prostate, gynecological, and liver cancers, he said.

IMRIS and Varian are co-developing the MR-guided radiation therapy system that combines IMRIS's proprietary MR imaging technology with Varian's TrueBeam system to enable the use of MR imaging during radiotherapy treatments for cancer.  The two companies are collaborating with the team at The Princess Margaret Cancer Centre and UHN's Techna Institute in Toronto to develop the system, which is not cleared for sale in any jurisdiction at this time.

About IMRIS
IMRIS (NASDAQ: IMRS; TSX: IM) is a global leader in providing image guided therapy solutions through its VISIUS Surgical Theatre – a revolutionary, multifunctional surgical environment that provides unmatched intraoperative vision to clinicians to assist in decision making and enhance precision in treatment. The multi-room suites incorporate diagnostic quality high-field MR, CT and angio modalities accessed effortlessly in the operating room setting. VISIUS Surgical Theatres serve the neurosurgical, spinal, cardiovascular and cerebrovascular markets and have been selected by 54 leading medical institutions around the world.

For further information, please contact:
Kelly McNeill
Chief Financial Officer
IMRIS Inc.
Tel: 763-203-6304
Email: kmcneill@imris.com

About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes, digital detectors, and image processing workstations for X-ray imaging in medical, scientific, and industrial applications and also supplies high-energy X-ray devices for cargo screening and non-destructive testing applications. Varian Medical Systems employs approximately 6350 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.

Meryl Ginsberg
Director of Public Relations
Varian Medical Systems
Tel: 650-996-7487
Email: meryl.ginsberg@varian.com


'/>"/>
SOURCE Varian Medical Systems
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prolong Pharmaceuticals Presents Novel Multi-Pronged Approach To Treating Sickle Cell Disease At The SCDAA Meeting
2. MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
3. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
4. VisionCare Ophthalmic Technologies Secures Up To $15MM To Accelerate Growth Of Its Novel Treatment For Age-Related Macular Degeneration
5. Bayer and the Broad Institute Join Forces to Develop Novel Treatment Options in Cancer Therapy
6. NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
7. Debiopharm Group and TCG Lifesciences Ltd. Enter into an Exclusive Research Agreement to Develop a Novel Class of Antibiotics, a New Strategic Therapeutic Area for Debiopharm
8. KemPharm Continues to Expand its Pain Therapy Pipeline with Discovery of KP606, a Novel Prodrug of Oxycodone
9. Among the Novel Oral Anticoagulants, Bayer/Janssens Xarelto is Positioned To Be the Sales-Leading Therapy for Venous Thromboembolism (VTE)
10. Novel LABA/LAMA Products Will Capture Greater Market Share than the LABA/ICS or LAMA Drug Classes by 2022
11. The Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by the Launch of Novel Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... HALLANDALE, Fla. , Feb. 9, 2016  Until ... sagging were surgery or liposuction. Thankfully, the FDA approved ... freezing them to death. Coolsculpting was originally approved in ... to the thighs and now the chin. With this ... Wellness Center can use a smaller applicator, the CoolMini, ...
(Date:2/10/2016)... , Feb. 9, 2016 On ... Administration (FDA) met with its Arthritis Advisory ... biosimilar of Johnson & Johnson,s Remicade and ... approved in the U.S. The Biologics Prescribers ... groups - Alliance for Patient Access, American ...
(Date:2/10/2016)... CTI BioPharma Corp. (CTI BioPharma) (NASDAQ ... the clinical studies being conducted under the Company,s ... the issuance of the Company,s February 8, 2016, ... by the U.S. Food and Drug Administration (FDA) ... oral communication from the FDA followed by a ...
Breaking Medicine Technology:
(Date:2/10/2016)... California (PRWEB) , ... February 09, 2016 , ... ... students, faculty and staff helped give free oral screenings to 150 children in ... 5, 2016. , The College of Dental Medicine joined Chinese American Dental Society ...
(Date:2/9/2016)... Fort Lauderdale, Florida (PRWEB) , ... February 09, 2016 , ... ... known as the Taste of South Florida Event, an upscale fundraiser held in South ... to wow sponsors and guests alike. This year the event will be held in ...
(Date:2/9/2016)... MA (PRWEB) , ... February 09, 2016 , ... ... (WCRI) compares the workers’ compensation fee schedule rates and Medicare rates for a ... services covered in the report, Evaluation of the 2015 Fee Schedule Rates ...
(Date:2/9/2016)... ... February 09, 2016 , ... On January 12, 2016 Paul McElwee, a ... they noticed their furnace not producing any heat. Shortly after entering the home, Paul ... exchanger was leaking dangerous levels of carbon monoxide into the home, at 2,000 parts ...
(Date:2/9/2016)... ... February 09, 2016 , ... METTLER TOLEDO ... lab personnel have a basic understanding of the techniques they use so they ... will help them reduce waste and rework to create a leaner overall lab ...
Breaking Medicine News(10 mins):